• Türkçe
    • English
  • Türkçe 
    • Türkçe
    • English
  • Giriş
Öğe Göster 
  •   RTEÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • TR-Dizin İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
  •   RTEÜ
  • Araştırma Çıktıları | TR-Dizin | WoS | Scopus | PubMed
  • TR-Dizin İndeksli Yayınlar Koleksiyonu
  • Öğe Göster
JavaScript is disabled for your browser. Some features of this site may not work without it.

Evaluation of the results of the use of two different anticoagulants in COVID-19 patients who were followed-up and treated in the intensive care unit

Thumbnail

Göster/Aç

Full Text / Tam Metin (124.7Kb)

Erişim

info:eu-repo/semantics/openAccess

Tarih

2023

Yazar

Kartal, Seyfi
Kongur, Esra
Özdemir, Abdullah
Öztürk, Çağatay Erman
Arslan, Mustafa

Üst veri

Tüm öğe kaydını göster

Künye

Kartal, S., Kongur, E., Özdemir, A., Öztürk, Ç.E. & Arslan, M. (2023). Evaluation of the Results of the Use of two Different Anticoagulants in COVID-19 Patients who Were Followed-Up and Treated in the Intensive Care Unit. Haydarpaşa Numune Medical Journal, 63(1), 40-45. http://doi.org/10.14744/hnhj.2021.60024

Özet

Introduction: The risk of thromboembolism increases due to tendency to coagulopathy, excessive inflammation, hypoxia, and immobility in patients who are treated of COVID-19 in Intensive Care Units (ICU). Therefore, thromboembolism prophylaxis (anticoagulant therapy) is recommended. There is no clear recommendation in the literature regarding the dose and duration of anticoagulant therapy. In this study, we evaluate of two different anticoagulant administrations in terms of prognosis and mortality in COVID-19 patients who were followed up and treated in the ICU. Methods: After the approval of the Ethics Committee, the study was carried out by retrospectively in ICU affiliated to three different centers. The patients were divided into two groups as those using anticoagulant at a prophylactic dose (Group 1) and treatment dose (Group 2). Various parameters of the patients were evaluated. Results: Of the 91 patients included in the study, 61.5% received prophylactic and 38.5% therapeutic anticoagulants. The rate of male patients 73.9% was found to be significantly higher in the mortal group (p=0.014). About 75.9% of the patients who received mechanical ventilation treatment and 13.59% of the patients who were not applied died (p<0.001). Mortality was higher in the group using prophylactic anticoagulants (58.39% vs. 37.1% p;0.043). Patients using prophylactic doses of anticoagulants had 2.42 times more mortality (Odds Ratio=2.42). Hb levels were found to be lower (p=0.017) and prothrombin time and partial prothrombine time values were long (p=0.048 and 0.038, respectively) in patients who received anticoagulants at the treatment dose. Discussion and Conclusion: Despite the increased tendency for thrombosis in COVID-19, there is no clear preventive or protective treatment. Hence, if there is no contraindicated situation, we believe that anticoagulants can be used safely at the treatment dose to avoid possible thromboembolic complications and reduce the risk of mortality. There is a need for largescale studies on dose selection in terms of prophylaxis.

Kaynak

Haydarpaşa Numune Medical Journal

Cilt

63

Sayı

1

Bağlantı

http://doi.org/10.14744/hnhj.2021.60024
https://hdl.handle.net/11436/8472

Koleksiyonlar

  • TF, Cerrahi Tıp Bilimleri Bölümü Koleksiyonu [1221]
  • TR-Dizin İndeksli Yayınlar Koleksiyonu [2844]



DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 




| Yönerge | Rehber | İletişim |

DSpace@RTEÜ

by OpenAIRE
Gelişmiş Arama

sherpa/romeo

Göz at

Tüm DSpaceBölümler & KoleksiyonlarTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına GöreBu KoleksiyonTarihe GöreYazara GöreBaşlığa GöreKonuya GöreTüre GöreDile GöreBölüme GöreKategoriye GöreYayıncıya GöreErişim ŞekliKurum Yazarına Göre

Hesabım

GirişKayıt

İstatistikler

Google Analitik İstatistiklerini Görüntüle

DSpace software copyright © 2002-2015  DuraSpace
İletişim | Geri Bildirim
Theme by 
@mire NV
 

 


|| Rehber|| Yönerge || Kütüphane || Recep Tayyip Erdoğan Üniversitesi || OAI-PMH ||

Recep Tayyip Erdoğan Üniversitesi, Rize, Türkiye
İçerikte herhangi bir hata görürseniz, lütfen bildiriniz:

Creative Commons License
Recep Tayyip Erdoğan Üniversitesi Institutional Repository is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 Unported License..

DSpace@RTEÜ:


DSpace 6.2

tarafından İdeal DSpace hizmetleri çerçevesinde özelleştirilerek kurulmuştur.